Intelligence Feed

Does BPC-157 have any solid human trial data?

I’m confused by peptide studies calling results “significant” when the sample is tiny and the endpoint is a mouse losing weight. Apparently statistics now includes optimism.

People oversimplify half-life a lot in peptide research. A 5-day half-life doesn’t automatically mean the effects last exactly 5 days, and a short half-life doesn’t mean a compound stops doing anything immediately. Absorption, active metabolites, receptor binding, and downstream signaling can all change the real duration of action. Half-life is useful, but it’s not the same thing as effect duration.

Simple endpoints win.

Mouse studies are doing a lot of heavy lifting. A peptide can improve glucose markers in rodents and still fail on durability, safety, or meaningful human outcomes. Yet the headline jumps straight to “longevity breakthrough.” More boring replication, fewer miracle claims built on a 12-week mouse experiment, please.

Mouse data ≠ humans

Comparing a mouse peptide study to a human trial is a bit like comparing a treadmill test to a marathon. People often see that a peptide “worked” in animals and assume the same dose and result should translate directly, but species metabolism, receptor sensitivity, half-life, and delivery method can all be different. Even the way the dose is reported matters: mg/kg in a mouse is not automatically an equivalent human dose. A promising mechanism is useful, but it is still only one step before knowing whether the effect is safe, repeatable, and meaningful in people.

bpc-157 human data?

Are GLP-1 studies really moving beyond weight loss, or are companies just finding new ways to market the same drugs? The heart and kidney research looks promising, but I’d like to see more long-term data before calling these peptides useful for everything.